Academic Journal
MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
| العنوان: | MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses |
|---|---|
| المؤلفون: | López-Gil, E., Moreno, Sandra, Ortego, Javier, Borrego, Belén, Lorenzo, Gema, Brun Torres, Alejandro |
| المساهمون: | Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Comunidad de Madrid, López-Gil, E., Moreno, Sandra, Ortego, Javier, Borrego, Belén, Lorenzo, Gema, Brun Torres, Alejandro |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute |
| سنة النشر: | 2020 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Gn Gc glycoproteins, Rift Valley fever virus (RVFV), Cellular response, Modified vaccinia Ankara (MVA), Neutralizing antibodies, Passive serum, Virus transfer |
| الوصف: | 15 Pág. ; In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a protective immune response in mice after a lethal RVFV challenge. Protection was related to the presence of glycoprotein specific CD8+ cells, with a low-level detection of in vitro neutralizing antibodies. In this work we extended those observations aimed to explore the role of humoral responses after MVA vaccination and to study the contribution of each glycoprotein antigen to the protective efficacy. Thus, we tested the efficacy and immune responses in BALB/c mice of recombinant MVA viruses expressing either glycoprotein Gn (rMVAGn) or Gc (rMVAGc). In the absence of serum neutralizing antibodies, our data strongly suggest that protection of vaccinated mice upon the RVFV challenge can be achieved by the activation of cellular responses mainly directed against Gc epitopes. The involvement of cellular immunity was stressed by the fact that protection of mice was strain dependent. Furthermore, our data suggest that the rMVA based single dose vaccination elicits suboptimal humoral immune responses against Gn antigen since disease in mice was exacerbated upon virus challenge in the presence of rMVAGnGc or rMVAGn immune serum. Thus, Gc-specific cellular immunity could be an important component in the protection after the challenge observed in BALB/c mice, contributing to the elimination of infected cells reducing morbidity and mortality and counteracting the deleterious effect of a subneutralizing antibody immune response. ; This work was supported by grants AGL-2011-22485, AGL-2017-83226R from the Spanish Ministry of Science and S2013/ABI-2906, S2018/BAA-4370 from Comunidad de Madrid. ELG was a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2076-393X |
| Relation: | #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/MICINN//AGL2011-22485/ES/VACUNAS FRENTE A LA FIEBRE DEL VALLE DEL RIFT: IDENTIFICACION DE DETERMINANTES ANTIGENICOS CRITICOS Y MECANISMOS INVOLUCRADOS EN PROTECCION/; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2017-83226-R/ES/UTILIZACION DEL VIRUS DE LA FIEBRE DEL VALLE DEL RIFT COMO VECTOR VACUNAL: MEJORA RACIONAL DE SU SEGURIDAD, ESTABILIDAD Y TRAZABILIDAD/; S2013/ABI-2906; S2018/BAA-4370; Centro de Investigación en Sanidad Animal (CISA); Publisher's version; https://doi.org/10.3390/vaccines8010082; Sí; Vaccines 8(1): e82 (2020); http://hdl.handle.net/10261/343071; http://dx.doi.org/10.13039/100012818; http://dx.doi.org/10.13039/501100004837; http://dx.doi.org/10.13039/501100011033; 2-s2.0-85079441607; https://api.elsevier.com/content/abstract/scopus_id/85079441607 |
| DOI: | 10.3390/vaccines8010082 |
| DOI: | 10.13039/100012818 |
| DOI: | 10.13039/501100004837 |
| DOI: | 10.13039/501100011033 |
| الاتاحة: | http://hdl.handle.net/10261/343071 https://doi.org/10.3390/vaccines8010082 https://doi.org/10.13039/100012818 https://doi.org/10.13039/501100004837 https://doi.org/10.13039/501100011033 https://api.elsevier.com/content/abstract/scopus_id/85079441607 |
| Rights: | open |
| رقم الانضمام: | edsbas.8A9F610F |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 2076393X |
|---|---|
| DOI: | 10.3390/vaccines8010082 |